Connecting investors and companies

We do not find any grounds in the announcement itself for yesterday’s sharp price increase of approximately 30%.

We believe Harvia's target markets will continue to grow in the coming years, and the company will be able to continue gaining market share.

Verve reported its Q1 figures broadly in line with our expectations, with strong operating cash flow as the standout.

15:17

Posti Group was listed on Nasdaq Helsinki in October 2025.

The stock is trading near the lower end of our estimated fair value range (EUR 0.7-1.5).

Solwers' Q1 was weaker than our expectations, and the income lines, which are important for deleveraging, remained slightly below even the weak comparison period.

18:58

Rob Kolkman, CEO, talks about media and learning company Sanoma as an investment.

11:12

Tokmanni’s Q1 was a bit weak, with Dollarstore dragging down the group’s earnings.

The improvement in loan terms is expected as the balance sheet has strengthened.

Bioretec's start to the year offered a positive surprise.

The target of 15-25% annual growth and an EBIT margin of 10-15% is in line with our previous expectations.

We cut our estimates, especially for the current year, in the wake of the profit warning issued by the company before the earnings release.

The new memorandum of understanding will expand blood analysis to the longevity programs in Switzerland and South Africa as early as this summer.

The acquisition complements UB's offerings, and Fondita ending up with UB was a surprise to us.